KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $56.0 million.

  • Moderna's Cash from Financing Activities fell 109.09% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 118.00%. This contributed to the annual value of $56.0 million for FY2024, which is 104.07% up from last year.
  • Per Moderna's latest filing, its Cash from Financing Activities stood at $56.0 million for FY2024, which was up 104.07% from -$1.4 billion recorded in FY2023.
  • In the past 5 years, Moderna's Cash from Financing Activities ranged from a high of $2.0 billion in FY2020 and a low of -$3.4 billion during FY2022.
  • Its 3-year average for Cash from Financing Activities is -$1.6 billion, with a median of -$1.4 billion in 2023.
  • In the last 5 years, Moderna's Cash from Financing Activities surged by 3,809.62% in 2020 and then plummeted by 294.96% in 2022.
  • Yearly analysis of 5 years shows Moderna's Cash from Financing Activities stood at $2.0 billion in 2020, then slumped by 142.94% to -$873.0 million in 2021, then tumbled by 294.96% to -$3.4 billion in 2022, then soared by 60.06% to -$1.4 billion in 2023, then soared by 104.07% to $56.0 million in 2024.